Lexicon Pharmaceuticals, Inc. (LXRX)
LXRX moved a median of +0.29% 30 minutes after news, and +0.62% by the close. How LXRX actually reacts to news — the realized, point-in-time move the market made, measured across 339 labeled events over the last three years with zero look-ahead.
LXRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.35% | 54% | 339 |
| 30-min | +0.29% | 51% | 339 |
| 60-min | 0.00% | 49% | 339 |
| to close | +0.62% | 56% | 339 |
| Middle 50% of LXRX reactions | -1.73% to +2.74% |
|---|---|
| Median reaction (30-min) | +0.29% |
| Measured reactions | 339 |
Half of all Lexicon Pharmaceuticals, Inc. news events land between -1.73% and +2.74% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LXRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 12 | +0.13% | 58% | -1.91% |
| Rating reiterations | 72 | -0.24% | 44% | -0.29% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how LXRX ranks against every other measured name →
That’s how LXRX usually reacts — get an email when it moves on news →Email me when LXRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LXRX's baseline. Nothing else.
Recent LXRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences | Press release | GlobeNewswire | +1.58% | +1.36% | |
| Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure | Press release | GlobeNewswire | -0.88% | -0.88% | |
| Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 | Press release | GlobeNewswire | +0.17% | +0.00% | |
| Form EFFECT LEXICON PHARMACEUTICALS, | SEC filing · Form EFFECT | SEC EDGAR | +0.61% | +1.30% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.75% | +2.07% | |
| Form 8-K LEXICON PHARMACEUTICALS, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +19.58% | +20.41% | |
| Form S-3 LEXICON PHARMACEUTICALS, | SEC filing · Form S-3 | SEC EDGAR | -4.75% | +2.07% | |
| Form S-8 LEXICON PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | -4.75% | +2.07% | |
| Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates | Press release | GlobeNewswire | +19.58% | +20.41% | |
| Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | GlobeNewswire | +1.08% | +0.86% | |
| Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) | Press release | GlobeNewswire | +1.26% | -3.04% | |
| Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions | Press release | GlobeNewswire | +2.06% | +0.54% | |
| Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +1.84% | +1.84% | |
| Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference | Press release | GlobeNewswire | +3.90% | +4.33% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.18% | +18.34% | |
| Form 8-K LEXICON PHARMACEUTICALS, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -4.85% | +1.82% | |
| Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates | Press release | GlobeNewswire | -4.85% | +1.82% | |
| Form 8-K LEXICON PHARMACEUTICALS, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -4.85% | +1.82% | |
| Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital | Press release | GlobeNewswire | -0.63% | +3.13% | |
| Form 8-K LEXICON PHARMACEUTICALS, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | +2.52% | |
| Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | GlobeNewswire | +2.21% | +1.90% | |
| Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting | Press release | GlobeNewswire | +1.07% | +0.54% | |
| Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo | Press release | GlobeNewswire | +3.07% | +5.52% | |
| Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 | Press release | GlobeNewswire | +1.91% | +5.13% | |
| Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.86% | +1.25% | |
| Form DEF 14A LEXICON PHARMACEUTICALS, For: Mar 16 | SEC filing · Form DEF | SEC EDGAR | +1.86% | +1.25% | |
| Form DEFA14A LEXICON PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | +1.86% | +1.25% | |
| Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes | Press release | GlobeNewswire | -1.81% | +3.61% | |
| Form 10-K LEXICON PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.52% | +4.27% | |
| Form 8-K LEXICON PHARMACEUTICALS, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -3.25% | +6.49% | |
| Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates | Press release | GlobeNewswire | -3.25% | +6.49% | |
| Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences | Press release | GlobeNewswire | -2.12% | -1.21% | |
| Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 | Press release | GlobeNewswire | -0.34% | +1.35% | |
| Form D LEXICON PHARMACEUTICALS, | SEC filing · Form D | SEC EDGAR | +0.76% | +0.00% | |
| Form PRE 14A LEXICON PHARMACEUTICALS, For: Feb 17 | SEC filing · Form PRE | SEC EDGAR | +0.76% | +0.00% | |
| Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement | Press release | GlobeNewswire | -2.85% | -2.44% | |
| Form 8-K LEXICON PHARMACEUTICALS, For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | -0.52% | +2.40% | |
| Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement | Press release | GlobeNewswire | -3.57% | -7.94% | |
| Form 8-K LEXICON PHARMACEUTICALS, For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | -3.57% | -7.94% | |
| Lexicon Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -3.57% | -7.94% | |
| Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary | Press release | GlobeNewswire | -0.84% | -4.49% | |
| Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain | Press release | GlobeNewswire | +2.24% | +16.42% | |
| Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.43% | +2.61% | |
| Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” | Press release | GlobeNewswire | -0.42% | -0.85% | |
| Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +2.19% | +2.63% | |
| Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 | Press release | GlobeNewswire | -1.13% | -0.75% | |
| Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum | Press release | GlobeNewswire | +0.83% | -1.41% | |
| Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences | Press release | GlobeNewswire | -1.04% | -2.08% | |
| Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference | Press release | GlobeNewswire | -0.58% | +12.23% | |
| Form 8-K LEXICON PHARMACEUTICALS, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | +12.23% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LXRX section they belong to.
Where else LXRX is measured.
LXRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cidara Therapeutics, Inc. (CDTX) | 339 | +0.06% | 52% |
| DaVita Inc. (DVA) | 339 | +0.07% | 53% |
| Cellect Biotechnology Ltd. - American Depositary Shares (APOP) | 337 | -0.42% | 35% |
| Cardinal Health, Inc. (CAH) | 335 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lexicon Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled LXRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 339 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of LXRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LXRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.